Roche gets early appeal on Taq patents:
This article was originally published in Clinica
Roche has persuaded a US appeal court to consider separately two of its PCR patents that were challenged in a federal district court decision in favour of Promega. According to Roche, Promega's actions directly infringed two US PCR patents, 4,638,195 and 4,683,202 and Promega's actions to induce others to use the native Taq enzyme for PCR procedures indirectly infringed the PCR patents. In December Promega won a decision against Roche concerning natural Taq which Promega claimed could have jeopardised Roche's entire PCR patent portfolio (see Clinica No 888, p 7).
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.